1.. Drug safety measures presented by MHLW (in Japanese) , https://www.mhlw.go.jp/shingi/2009/08/dl/s0821-4d.pdf (accessed 15 June 2021).
Google Scholar2.. Pharmacovigilance: overview , https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance-overview (accessed 15 June 2021).
Google Scholar3.. Postmarketing surveillance programs , https://www.fda.gov/drugs/surveillance/postmarketing-surveillance-programs (accessed 15 June 2021).
Google Scholar4.. Periodic safety update reports (PSURs) , https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/periodic-safety-update-reports-psurs (accessed 15 June 2021).
Google Scholar5.. 21 CFR 314.80(c)(2), CFR – Code of Federal Regulations Title 21 , https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.80 (accessed 15 June 2021).
Google Scholar6.. Post-authorisation safety studies (PASS) , https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/post-authorisation-safety-studies-pass-0 (accessed 15 June 2021).
Google Scholar7.. Postmarketing requirements and commitments: introduction , https://www.fda.gov/drugs/guidance-compliance-regulatory-information/postmarket-requirements-and-commitments (accessed 15 June 2021).
Google Scholar8.. Post-marketing surveillance and safety management . Chapter 4, regulatory affairs in Japan (in Japanese), http://www.jpma.or.jp/about/issue/gratis/pdf/17yakuji_ch04.pdf (accessed 13 September 2020).
Google Scholar9.. Mori, E, Kaneko, M, Narukawa, M. The current status of all-case surveillance study in Japan and factors influencing the judgement of its necessity. Jpn J Clin Pharmacol Ther 2015; 46(4): 185–189 (in Japanese), https://www.jstage.jst.go.jp/article/jscpt/46/4/46_185/_pdf/ (accessed 1 September 2020).
Google Scholar | Crossref10.. QAs related to post-marketing all-case surveillance for drugs (in Japanese) , https://www.pmda.go.jp/files/000231052.pdf (accessed 1 September 2020).
Google Scholar11.. Research on the situation and implications of the post-marketing all-case surveillance study in Japan (in Japanese) ,https://www.jstage.jst.go.jp/article/rsmp/4/3/4_199/_pdf/-char/ja (accessed 1 September 2020).
Google Scholar12.. PMDA website for search of drugs (in Japanese) , https://www.pmda.go.jp/PmdaSearch/iyakuSearch/ (accessed 1 September 2020).
Google Scholar13.. History , https://www.pmda.go.jp/english/about-pmda/outline/0002.html (accessed 13 September 2020).
Google Scholar14.. PMDA performance report in Fiscal Year 2018 (in Japanese) , https://www.pmda.go.jp/files/000233399.pdf (accessed 13 September 2020).
Google Scholar15.. Post-marketing all-case surveillance – current status and future in Japan . PMDA presentation material in Anti-Tumor Drug Development Forum in June 2012 (in Japanese), https://www.pmda.go.jp/files/000164164.pdf (accessed 13 September 2020).
Google Scholar16.. Post-authorisation efficacy studies: questions and answers , https://www.ema.europa.eu/en/human-regulatory/post-authorisation/post-authorisation-efficacy-studies-questions-answers (accessed 15 June 2021).
Google Scholar17.. Urgent safety information (in Japanese) , https://www.pmda.go.jp/safety/info-services/drugs/calling-attention/esc-rsc/0001.html (accessed 13 September 2020).
Google Scholar18.. Re-examination report for Naglazyme issued on August 2, 2019 (in Japanese) , https://www.pmda.go.jp/drugs_reexam/2019/P20191001003/641173000_22000AMX01523_A100_1.pdf (accessed 1 September 2020).
Google Scholar19.. Reexamination report for Concerta issued on October 7, 2019 (in Japanese) , https://www.pmda.go.jp/drugs_reexam/2019/P20191114002/800155000_21900AMX01770_A100_1.pdf (accessed 1 September 2020).
Google Scholar20.. Act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices , http://www.japaneselawtranslation.go.jp/law/detail/?id=3213&vm=04&re=01 (accessed 1 September 2020).
Google Scholar21.. Ultra-orphan medicines for extremely rare conditions . Scottish Medicines Consortium, https://www.scottishmedicines.org.uk/how-we-decide/ultra-orphan-medicines-for-extremely-rare-conditions/ (accessed 1 September 2020).
Google Scholar22.. Naglazyme: EPAR – risk-management-plan summary , https://www.ema.europa.eu/en/documents/rmp-summary/naglazyme-epar-risk-management-plan-summary_en.pdf (accessed 15 June 2021).
Google Scholar23.. Postmarket requirements and commitments (searching with Naglazyme) , https://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm (accessed 15 June 2021).
Google Scholar24.. Pharmaceuticals and medical devices safety information no. 334, June 2016 , https://www.pmda.go.jp/files/000212847.pdf (accessed 19 March 2021).
Google Scholar